Showing posts from October, 2023Show all
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy health-issue

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Nitesh sinha October 27, 2023

https://ift.tt/qbCSriy   from Sanofi - Aventis Groupe https://ift.tt/VYBMd1I via IFTTT

Read more
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) health-issue

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Nitesh sinha October 22, 2023

https://ift.tt/JzVhxu4 Dupixent ® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosin…

Read more
Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria health-issue

Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Nitesh sinha October 20, 2023

https://ift.tt/SXuAEK5 from Sanofi - Aventis Groupe https://ift.tt/xFJciLb via IFTTT

Read more
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio health-issue

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Nitesh sinha October 19, 2023

https://ift.tt/LFGiEX9 Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio from Sanofi - Aventis Groupe https://ift.t…

Read more
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM health-issue

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

Nitesh sinha October 18, 2023

https://ift.tt/N5FdVen   from Sanofi - Aventis Groupe https://ift.tt/3RdVSBj via IFTTT

Read more
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis health-issue

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Nitesh sinha October 13, 2023

https://ift.tt/4izlXwW from Sanofi - Aventis Groupe https://ift.tt/5Ve82K7 via IFTTT

Read more
Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease health-issue

Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease

Nitesh sinha October 06, 2023

https://ift.tt/KICSPgZ from Sanofi - Aventis Groupe https://ift.tt/KNaeq0i via IFTTT

Read more
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment health-issue

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Nitesh sinha October 03, 2023

https://ift.tt/zwy9pdD Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment from Sanofi - Aventi…

Read more
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli health-issue

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Nitesh sinha October 03, 2023

https://ift.tt/oC9faBv from Sanofi - Aventis Groupe https://ift.tt/8ZcuU1Q via IFTTT

Read more
Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs health-issue

Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs

Nitesh sinha October 01, 2023

https://ift.tt/Gb8TPwF   from Sanofi - Aventis Groupe https://ift.tt/COeHcgN via IFTTT

Read more